Insomnia and occupational medicine | Prise en charge de l’insomnie en médecine du travail

V. Bayon, E. Prévot, A. Metlaine, D. Choudat, P. Philip, D. Léger
Archives des Maladies Professionnelles et de l'Environnement. 2009-06-01; 70(3): 296-299
DOI: 10.1016/j.admp.2009.01.006

PubMed
Read on PubMed



1. IUBMB Life. 2015 Apr;67(4):239-54. doi: 10.1002/iub.1366. Epub 2015 Apr 21.

Prohibitin 2: At a communications crossroads.

Bavelloni A(1)(2), Piazzi M(3), Raffini M(2), Faenza I(3), Blalock WL(1)(4).

Author information:
(1)Laboratory of Musculoskeletal Cell Biology, Rizzoli Orthopedic Institute,
Bologna, Italy.
(2)Laboratory RAMSES, Rizzoli Orthopedic Institute, Bologna, Italy.
(3)Department of Biomedical Sciences, University of Bologna, Bologna, Italy.
(4)National Research Council of Italy, Institute of Molecular Genetics, Bologna,
Italy.

Prohibitins (PHBs) are a highly conserved class of proteins first discovered as
inhibitors of cellular proliferation. Since then PHBs have been found to have a
significant role in transcription, nuclear signaling, mitochondrial structural
integrity, cell division, and cellular membrane metabolism, placing these
proteins among the key regulators of pathologies such as cancer, neuromuscular
degeneration, and other metabolic diseases. The human genome encodes two PHB
proteins, prohibitin 1 (PHB1) and prohibitin 2 (PHB2), which function not only as
a heterodimeric complex, but also independently. While many previous reviews have
focused on the better characterized prohibitin, PHB1, this review focuses on PHB2
and new data concerning its cellular functions both in complex with PHB1 and
independent of PHB1.

© 2015 International Union of Biochemistry and Molecular Biology.

DOI: 10.1002/iub.1366
PMID: 25904163 [Indexed for MEDLINE]

Know more about